Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2579-2588

  Vigne, Solenne ^a   Duraffour, Sophie ^b   Andrei, Graciela ^b   Snoeck, Robert ^b   Garin, Daniel ^a,c   Crance, Jean Marc ^a  

^a CENTRE DE RECHERCHES   (France)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c Ecole du Val de Grace   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CIDOFOVIR; MESSENGER RNA; NUCLEOSIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; SMALL INTERFERING B1R 2; SMALL INTERFERING D5R 2; SMALL INTERFERING G7L 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; B1R GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; G7L GENE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MONKEYPOX VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOPOXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; RNA INTERFERENCE; VACCINIA VIRUS; VIRUS GENE; VIRUS INHIBITION; VIRUS MUTANT; VIRUS PLAQUE; VIRUS RESISTANCE; WILD TYPE;

ANTIVIRAL AGENTS; CELL LINE; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; HUMANS; INTERFERON-GAMMA; PHOSPHONIC ACIDS; RNA, SMALL INTERFERING; VACCINIA VIRUS; VIRAL CORE PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 67049107832     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01626-08     Document Type: Article

References (74)

1. Alibek, K. 1999. The Soviet Union's anti-agricultural biological weapons. Ann. N. Y. Acad. Sci. 894:18-19.
2. Allen, L. B., L. K. Vanderslice, C. M. Fingal, F. H. McCright, E. F. Harris, and P. D. Cook. 1982. Evaluation of the anti-herpesvirus drug combinations: virazole plus arabinofuranosylhypoxanthine and virazole plus arabinofuranosyladenine. Antivir. Res. 2:203-216.
3. Amarzguioui, M., T. Holen, E. Babaie, and H. Prydz. 2003. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31: 589-595. (Pubitemid 36175948)
4. Andrei, G., D. B. Gammon, P. Fiten, E. De Clercq, G. Opdenakker, R. Snoeck, and D. H. Evans. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80:9391-9401. (Pubitemid 44435618)
5. Ashford, D. A., R. M. Kaiser, M. E. Bales, K. Shutt, A. Patrawalla, A. McShan, J. W. Tappero, B. A. Perkins, and A. L. Dannenberg. 2003. Planning against biological terrorism: lessons from outbreak investigations. Emerg. Infect. Dis. 9:515-519.
6. Assarsson, E., J. A. Greenbaum, M. Sundstrom, L. Schaffer, J. A. Hammond, V. Pasquetto, C. Oseroff, R. C. Hendrickson, E. J. Lefkowitz, D. C. Tscharke, J. Sidney, H. M. Grey, S. R. Head, B. Peters, and A. Sette. 2008. Kinetic analysis of a complete poxvirus transcriptome reveals an intermediate-early class of genes. Proc. Natl. Acad. Sci. USA 105:2140-2145.
7. Banham, A. H., and G. L. Smith. 1992. Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. Virology 191:803-812. (Pubitemid 23022485)
8. Bayry, J., and D. F. Tough. 2005. Is RNA interference feasible for the control of foot-and-mouth disease outbreaks? Trends Immunol. 26:238-239.
9. Bitko, V., and S. Barik. 2001. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 1:34. (Pubitemid 38904566)
10. Bitko, V., A. Musiyenko, O. Shulyayeva, and S. Barik. 2005. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11:50-55.
11. Boyle, K. A., and P. Traktman. 2004. Members of a novel family of mammalian protein kinases complement the DNA-negative phenotype of a vaccinia virus ts mutant defective in the B1 kinase. J. Virol. 78:1992-2005.
12. Briolant, S., D. Garin, N. Scaramozzino, A. Jouan, and J. M. Crance. 2004. Inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antivir. Res. 61:111-117.
13. Cono, J., C. G. Casey, and D. M. Bell. 2003. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep. 52:1-28.
14. Dahlgren, C., H. Y. Zhang, Q. Du, M. Grahn, G. Norstedt, C. Wahlestedt, and Z. Liang. 2008. Analysis of siRNA specificity on targets with doublenucleotide mismatches. Nucleic Acids Res. 36:e53. (Pubitemid 351751865)
15. Dave, R. S., J. P. McGettigan, T. Qureshi, M. J. Schnell, G. Nunnari, and R. J. Pomerantz. 2006. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology 348:489-497.
16. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 55:1-13.
17. DeVincenzo, J., J. E. Cehelsky, R. Alvarez, S. Elbashir, J. Harborth, I. Toudjarska, L. Nechev, V. Murugaiah, A. Van Vliet, A. K. Vaishnaw, and R. Meyers. 2008. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antivir. Res. 77:225-231.
18. Du, Q., H. Thonberg, J. Wang, C. Wahlestedt, and Z. Liang. 2005. A systematic analysis of the silencing effects of an active siRNA at all singlenucleotide mismatched target sites. Nucleic Acids Res. 33:1671-1677. (Pubitemid 41418395)
19. Duraffour, S., R. Snoeck, M. Krecmerova, J. van Den Oord, R. De Vos, A. Holy, J. M. Crance, D. Garin, E. De Clercq, and G. Andrei. 2007. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob. Agents Chemother. 51:4410-4419.
20. Elbashir, S. M., W. Lendeckel, and T. Tuschl. 2001. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188-200. (Pubitemid 32107664)
21. Elion, G. B., S. Singer, and G. H. Hitchings. 1954. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
22. Evans, E., and P. Traktman. 1987. Molecular genetic analysis of a vaccinia virus gene with an essential role in DNA replication. J. Virol. 61:3152-3162. (Pubitemid 17131494)
23. Ferrier, A., D. Garin, and J. M. Crance. 2004. Rapid inactivation of vaccinia virus in suspension and dried on surfaces. J. Hosp. Infect. 57:73-79.
24. Fivelman, Q. L., I. S. Adagu, and D. C. Warhurst. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48:4097-4102. (Pubitemid 39434861)
25. Gammon, D. B., R. Snoeck, P. Fiten, M. Krecmerova, A. Holy, E. De Clercq, G. Opdenakker, D. H. Evans, and G. Andrei. 2008. Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 82:12520-12534.
26. Ge, Q., L. Filip, A. Bai, T. Nguyen, H. N. Eisen, and J. Chen. 2004. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101:8676-8681.
27. Geisbert, T. W., L. E. Hensley, E. Kagan, E. Z. Yu, J. B. Geisbert, K. Daddario-DiCaprio, E. A. Fritz, P. B. Jahrling, K. McClintock, J. R. Phelps, A. C. Lee, A. Judge, L. B. Jeffs, and I. MacLachlan. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193:1650-1657.
28. Giladi, H., M. Ketzinel-Gilad, L. Rivkin, Y. Felig, O. Nussbaum, and E. Galun. 2003. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 8:769-776.
29. Hall, M. J., R. F. Middleton, and D. Westmacott. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11:427-433.
30. Hamasaki, K., K. Nakao, K. Matsumoto, T. Ichikawa, H. Ishikawa, and K. Eguchi. 2003. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. 543:51-54. (Pubitemid 36577226)
31. Jacque, J. M., K. Triques, and M. Stevenson. 2002. Modulation of HIV-1 replication by RNA interference. Nature 418:435-438. (Pubitemid 34826845)
32. Jawetz, E. 1967. Combined antibiotic action: some definitions and correlations between laboratory and clinical results. Antimicrob. Agents Chemother. 7:203-209.
33. Jordan, R., D. Tien, T. C. Bolken, K. F. Jones, S. R. Tyavanagimatt, J. Strasser, A. Frimm, M. L. Corrado, P. G. Strome, and D. E. Hruby. 2008. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52:1721-1727.
34. Judge, A. D., V. Sood, J. R. Shaw, D. Fang, K. McClintock, and I. MacLachlan. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23:457-462.
35. Kornbluth, R. S., D. F. Smee, R. W. Sidwell, V. Snarsky, D. H. Evans, and K. Y. Hostetler. 2006. Mutations in the E9L polymerase gene of cidofovirresistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 50:4038-4043.
36. Kumar, P., H. S. Ban, S. S. Kim, H. Wu, T. Pearson, D. L. Greiner, A. Laouar, J. Yao, V. Haridas, K. Habiro, Y. G. Yang, J. H. Jeong, K. Y. Lee, Y. H. Kim, S. W. Kim, M. Peipp, G. H. Fey, N. Manjunath, L. D. Shultz, S. K. Lee, and P. Shankar. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134:577-586.
37. Lacy, S. A., M. J. Hitchcock, W. A. Lee, P. Tellier, and K. C. Cundy. 1998. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44:97-106.
38. Lalezari, J. P., R. J. Stagg, B. D. Kuppermann, G. N. Holland, F. Kramer, D. V. Ives, M. Youle, M. R. Robinson, W. L. Drew, and H. S. Jaffe. 1997. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 126:257-263.
39. Li, B. J., Q. Tang, D. Cheng, C. Qin, F. Y. Xie, Q. Wei, J. Xu, Y. Liu, B. J. Zheng, M. C. Woodle, N. Zhong, and P. Y. Lu. 2005. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat. Med. 11:944-951.
40. Mahr, A., and B. E. Roberts. 1984. Arrangement of late RNAs transcribed from a 7.1-kilobase EcoRI vaccinia virus DNA fragment. J. Virol. 49:510-520. (Pubitemid 14175227)
41. Martinez, J., and T. Tuschl. 2004. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev. 18:975-980. (Pubitemid 38620238)
42. McCaffrey, A. P., L. Meuse, T. T. Pham, D. S. Conklin, G. J. Hannon, and M. A. Kay. 2002. RNA interference in adult mice. Nature 418:38-39. (Pubitemid 34742563)
43. McCaffrey, A. P., H. Nakai, K. Pandey, Z. Huang, F. H. Salazar, H. Xu, S. F. Wieland, P. L. Marion, and M. A. Kay. 2003. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21:639-644.
44. Mercer, J., and P. Traktman. 2005. Genetic and cell biological characterization of the vaccinia virus A30 and G7 phosphoproteins. J. Virol. 79:7146-7161. (Pubitemid 40677345)
45. Morrissey, D. V., K. Blanchard, L. Shaw, K. Jensen, J. A. Lockridge, B. Dickinson, J. A. McSwiggen, C. Vargeese, K. Bowman, C. S. Shaffer, B. A. Polisky, and S. Zinnen. 2005. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41:1349-1356. (Pubitemid 40770288)
46. Morrissey, D. V., J. A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, N. Vaish, S. Zinnen, C. Vargeese, K. Bowman, C. S. Shaffer, L. B. Jeffs, A. Judge, I. MacLachlan, and B. Polisky. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23:1002-1007.
47. Moss, B. 2001. Poxviridae: the viruses and their replication, p. 2849-2883. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol.2. Lippincott Williams & Wilkins, Philadelphia, PA.
48. Moss, B., and B. M. Ward. 2001. High-speed mass transit for poxviruses on microtubules. Nat. Cell Biol. 3:E245-E246.
49. Nakata, H., S. M. Steinberg, Y. Koh, K. Maeda, Y. Takaoka, H. Tamamura, N. Fujii, and H. Mitsuya. 2008. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob. Agents Chemother. 52:2111-2119.
50. Nichols, R. J., M. S. Wiebe, and P. Traktman. 2006. The vaccinia-related kinases phosphorylate the N′ terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol. Biol. Cell 17:2451-2464.
51. Nikonenko, B. V., K. A. Sacksteder, S. Hundert, L. Einck, and C. A. Nacy. 2008. Preclinical study of new TB drugs and drug combinations in mouse models. Recent Patents Anti-Infect. Drug Discov. 3:102-116.
52. Orent, W. 1998. Escape from Moscow. Sciences 3:26-31.
53. Palliser, D., D. Chowdhury, Q. Y. Wang, S. J. Lee, R. T. Bronson, D. M. Knipe, and J. Lieberman. 2006. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439:89-94. (Pubitemid 43053634)
54. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
55. Rempel, R. E., M. K. Anderson, E. Evans, and P. Traktman. 1990. Temperature-sensitive vaccinia virus mutants identify a gene with an essential role in viral replication. J. Virol. 64:574-583. (Pubitemid 20032668)
56. Rempel, R. E., and P. Traktman. 1992. Vaccinia virus B1 kinase: phenotypic analysis of temperature-sensitive mutants and enzymatic characterization of recombinant proteins. J. Virol. 66:4413-4426.
57. Santos, C. R., F. M. Vega, S. Blanco, R. Barcia, and P. A. Lazo. 2004. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology 328:254-265. (Pubitemid 39349474)
58. Selleseth, D. W., C. L. Talarico, T. Miller, M. W. Lutz, K. K. Biron, and R. J. Harvey. 2003. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 47:1468-1471.
59. Shin, S., and S. Lim. 2004. Antifungal effects of herbal essential oils alone and in combination with ketoconazole against Trichophyton spp. J. Appl. Microbiol. 97:1289-1296.
60. Shrivastava, N., and A. Srivastava. 2008. RNA interference: an emerging generation of biologicals. Biotechnol. J. 3:339-353.
61. Sledz, C. A., M. Holko, M. J. de Veer, R. H. Silverman, and B. R. Williams. 2003. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:834-839.
62. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
63. Song, E., S. K. Lee, D. M. Dykxhoorn, C. Novina, D. Zhang, K. Crawford, J. Cerny, P. A. Sharp, J. Lieberman, N. Manjunath, and P. Shankar. 2003. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 77:7174-7181. (Pubitemid 36734486)
64. Szajner, P., H. Jaffe, A. S. Weisberg, and B. Moss. 2003. Vaccinia virus G7L protein interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J. Virol. 77:3418-3429. (Pubitemid 36297261)
65. Tattersall, M. H., and K. R. Harrap. 1973. Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside. Eur. J. Cancer 9:229-232.
66. Tompkins, S. M., C. Y. Lo, T. M. Tumpey, and S. L. Epstein. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101:8682-8686.
67. Valderrama, F., J. V. Cordeiro, S. Schleich, F. Frischknecht, and M. Way. 2006. Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling. Science 311:377-381. (Pubitemid 43132662)
68. Vigne, S., R. Germi, S. Duraffour, S. Larrat, G. Andrei, R. Snoeck, D. Garin, and J. M. Crance. 2008. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. Antivir. Ther. 13:357-368.
69. Vigne, S., S. Duraffour, G. Andrei, R. Snoeck, D. Garin, and J. M. Crance. 2008. Anti-orthopoxviral potency of siRNAs targeting three genes of vaccinia virus, abstr. P8.107. Abstr. 17th Int. Poxvirus Iridovirus Conf.
70. White, R. L., D. S. Burgess, M. Manduru, and J. A. Bosso. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checker-board, and E test. Antimicrob. Agents Chemother. 40:1914-1918.
71. Wiebe, M. S., and P. Traktman. 2007. Poxviral B1 kinase overcomes barrier to autointegration factor, a host defense against virus replication. Cell Host Microbe 1:187-197. (Pubitemid 46706362)
72. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149. (Pubitemid 41433232)
73. Ying, R. S., C. Zhu, X. G. Fan, N. Li, X. F. Tian, H. B. Liu, and B. X. Zhang. 2007. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Antivir. Res. 73:24-30.
74. Zhang, W., H. Yang, X. Kong, S. Mohapatra, H. San Juan-Vergara, G. Hellermann, S. Behera, R. Singam, R. F. Lockey, and S. S. Mohapatra. 2005. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11:56-62.